CD8A and breast carcinoma: Fortunately, PTT stimulated by biomimetic membrane-coated NPs can be combined with checkpoint blockade mediated by PD-1 or CTLA-4 antibodies to reinstate CD8 + T cells’ normal activity and significantly increase immunotherapy success in basal-like breast cancer tumors [78].